ITEMS IN AFP WITH KEYWORD:
Feb 15, 2010 Issue
Combination Therapy for Postmenopausal Osteoporosis [FPIN's Clinical Inquiries]
There is insufficient evidence to recommend combination therapy for the routine management of postmenopausal osteoporosis.
The American College of Physicians (ACP) recently released guidelines on treatment of low bone mineral density (BMD) or osteoporosis to prevent fractures describes the available evidence on pharmacologic treatment in men and women.
Osteoporosis affects approximately 8 million women and 2 million men in the United States. The associated fractures are a common and preventable cause of morbidity and mortality in up to 50 percent of older women. The U.S. Preventive Services Task Force recommends using dual energy x-ray absorptiome...
Oct 1, 2008 Issue
ACP Guidelines on Screening for Osteoporosis in Men [Practice Guidelines]
Guidelines on screening for osteoporosis in men are available from the American College of Physicians (ACP). Although osteoporosis is commonly thought of as a disease that affects women, osteoporotic fractures also result in considerable morbidity and mortality in men.
Sep 1, 2008 Issue
Alendronate for Fracture Prevention in Postmenopause [Cochrane for Clinicians]
In postmenopausal women, a 10-mg daily dose of alendronate is effective for secondary (number needed to treat [NNT] = 16) and primary (NNT = 50) prevention of vertebral fractures. It is also effective for secondary prevention of nonvertebral fractures, including hip or wrist fractures (NNT = 100), b...
Zoledronic acid, in combination with calcium and vitamin D, will reduce the risk of vertebral fractures, and to a lesser extent, hip fractures in women with osteoporosis. It decreases subsequent fractures and mortality in high-risk patients who have had a hip fracture. Zoledronic acid may be most us...
Approximately one in six women will have a hip fracture during her lifetime, and approximately one in 35 of all women will die of complications from hip fracture.
The North American Menopause Society (NAMS) has updated its evidence-based guidelines on the diagnosis, prevention, and treatment of osteoporosis in postmenopausal women to address the need for standards of care as they relate to menopause-associated health conditions.
Ibandronate is a bisphosphonate that can be taken daily or monthly. The daily dosage has been shown to decrease vertebral fractures in women with osteoporosis and a history of previous vertebral fractures. Neither formulation has been shown to reduce the risk of hip fracture or other nonvertebral fr...